AMAG Pharma (AMAG) Misses Q4 EPS Views

AMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of $0.06, $0.24 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $53.3 million versus the consensus estimate of $52.69 million.

Non-GAAP adjusted EBITDA for the quarter ended December 31, 2014 was $14.5 million, as compared to negative $2.8 million for the same period in 2013. Non-GAAP adjusted EBITDA for 2014 was $14.3 million, as compared to negative $5.6 million for 2013.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c